Literature DB >> 9758152

Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids.

M Diana1, M Melis, G L Gessa.   

Abstract

The intravenous administration of the psychoactive constituent of marijuana, delta9-tetrahydrocannabinol (delta9-THC) (62.5-1000 microg/kg), and the synthetic cannabinoid agonist WIN 55212,2 (WIN) (62.5-500 microg/kg), produced a dose-related increase in the firing rate and burst firing in the majority of antidromically identified meso-prefrontal dopaminergic neurons. In a restricted number of neurons (n=4), WIN administration did not increase firing rate but produced an increment of bursting activity. These effects of the cannabinoids were reversed by the intravenous administration of SR 141716 A, a selective cannabinoid antagonist (1 mg/kg), per se ineffective to modify the electrical activity of dopaminergic neurons. The results indicate that stimulation of cannabinoid CB1 receptors produces an activation of meso-prefrontal dopaminergic transmission. Considering that supranormal stimulation of D1 dopamine receptors in the prefrontal cortex has been shown to impair working memory, the present results suggest that the negative effects of cannabinoids on cognitive processes might be related to the activation of dopaminergic transmission in the prefrontal cortex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758152     DOI: 10.1111/j.1460-9568.1998.00292.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  37 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Genetic Versus Pharmacological Assessment of the Role of Cannabinoid Type 2 Receptors in Alcohol Reward-Related Behaviors.

Authors:  Matthew S Powers; Kristen R Breit; Julia A Chester
Journal:  Alcohol Clin Exp Res       Date:  2015-12       Impact factor: 3.455

3.  Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide.

Authors:  Marcello Solinas; Gianluigi Tanda; Carrie E Wertheim; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

4.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 5.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

Review 6.  The acute effects of cannabinoids on memory in humans: a review.

Authors:  Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-09-26       Impact factor: 4.530

7.  Chronic adolescent exposure to delta-9-tetrahydrocannabinol in COMT mutant mice: impact on indices of dopaminergic, endocannabinoid and GABAergic pathways.

Authors:  Aine T Behan; Magdalena Hryniewiecka; Colm M P O'Tuathaigh; Anthony Kinsella; Mary Cannon; Maria Karayiorgou; Joseph A Gogos; John L Waddington; David R Cotter
Journal:  Neuropsychopharmacology       Date:  2012-03-21       Impact factor: 7.853

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 9.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Marijuana and cannabinoid regulation of brain reward circuits.

Authors:  Carl R Lupica; Arthur C Riegel; Alexander F Hoffman
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.